Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Acute Kidney Injury in Septic Patients Treated by Selected Nephrotoxic Antibiotic Agents-Pathophysiology and Biomarkers-A Review

N. Petejova, A. Martinek, J. Zadrazil, M. Kanova, V. Klementa, R. Sigutova, I. Kacirova, V. Hrabovsky, Z. Svagera, D. Stejskal

. 2020 ; 21 (19) : . [pub] 20200926

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012120

Acute kidney injury is a common complication in critically ill patients with sepsis and/or septic shock. Further, some essential antimicrobial treatment drugs are themselves nephrotoxic. For this reason, timely diagnosis and adequate therapeutic management are paramount. Of potential acute kidney injury (AKI) biomarkers, non-protein-coding RNAs are a subject of ongoing research. This review covers the pathophysiology of vancomycin and gentamicin nephrotoxicity in particular, septic AKI and the microRNAs involved in the pathophysiology of both syndromes. PubMED, UptoDate, MEDLINE and Cochrane databases were searched, using the terms: biomarkers, acute kidney injury, antibiotic nephrotoxicity, sepsis, miRNA and nephrotoxicity. A comprehensive review describing pathophysiology and potential biomarkers of septic and toxic acute kidney injury in septic patients was conducted. In addition, five miRNAs: miR-15a-5p, miR-192-5p, miR-155-5p, miR-486-5p and miR-423-5p specific to septic and toxic acute kidney injury in septic patients, treated by nephrotoxic antibiotic agents (vancomycin and gentamicin) were identified. However, while these are at the stage of clinical testing, preclinical and clinical trials are needed before they can be considered useful biomarkers or therapeutic targets of AKI in the context of antibiotic nephrotoxicity or septic injury.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012120
003      
CZ-PrNML
005      
20220808141037.0
007      
ta
008      
210420s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms21197115 $2 doi
035    __
$a (PubMed)32993185
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Petejova, Nadezda $u Department of Internal Medicine, University Hospital Ostrava, 70852 Ostrava, Czech Republic ; Department of Clinical Studies Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic ; Department of Internal Medicine III-Nephrology, Rheumatology and Endocrinology, University Hospital and Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
245    10
$a Acute Kidney Injury in Septic Patients Treated by Selected Nephrotoxic Antibiotic Agents-Pathophysiology and Biomarkers-A Review / $c N. Petejova, A. Martinek, J. Zadrazil, M. Kanova, V. Klementa, R. Sigutova, I. Kacirova, V. Hrabovsky, Z. Svagera, D. Stejskal
520    9_
$a Acute kidney injury is a common complication in critically ill patients with sepsis and/or septic shock. Further, some essential antimicrobial treatment drugs are themselves nephrotoxic. For this reason, timely diagnosis and adequate therapeutic management are paramount. Of potential acute kidney injury (AKI) biomarkers, non-protein-coding RNAs are a subject of ongoing research. This review covers the pathophysiology of vancomycin and gentamicin nephrotoxicity in particular, septic AKI and the microRNAs involved in the pathophysiology of both syndromes. PubMED, UptoDate, MEDLINE and Cochrane databases were searched, using the terms: biomarkers, acute kidney injury, antibiotic nephrotoxicity, sepsis, miRNA and nephrotoxicity. A comprehensive review describing pathophysiology and potential biomarkers of septic and toxic acute kidney injury in septic patients was conducted. In addition, five miRNAs: miR-15a-5p, miR-192-5p, miR-155-5p, miR-486-5p and miR-423-5p specific to septic and toxic acute kidney injury in septic patients, treated by nephrotoxic antibiotic agents (vancomycin and gentamicin) were identified. However, while these are at the stage of clinical testing, preclinical and clinical trials are needed before they can be considered useful biomarkers or therapeutic targets of AKI in the context of antibiotic nephrotoxicity or septic injury.
650    _2
$a akutní poškození ledvin $x chemicky indukované $x diagnóza $x etiologie $x patofyziologie $7 D058186
650    _2
$a zvířata $7 D000818
650    _2
$a antibakteriální látky $x škodlivé účinky $x terapeutické užití $7 D000900
650    _2
$a biologické markery $x analýza $7 D015415
650    _2
$a gentamiciny $x škodlivé účinky $x terapeutické užití $7 D005839
650    _2
$a lidé $7 D006801
650    _2
$a ledviny $x účinky léků $x patofyziologie $7 D007668
650    _2
$a mikro RNA $x analýza $7 D035683
650    _2
$a sepse $x komplikace $x diagnóza $x farmakoterapie $x patofyziologie $7 D018805
650    _2
$a vankomycin $x škodlivé účinky $x terapeutické užití $7 D014640
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Martinek, Arnost $u Department of Internal Medicine, University Hospital Ostrava, 70852 Ostrava, Czech Republic ; Department of Clinical Studies Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic
700    1_
$a Zadrazil, Josef $u Department of Internal Medicine III-Nephrology, Rheumatology and Endocrinology, University Hospital and Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
700    1_
$a Kanova, Marcela $u Department of Anesthesiology and Resuscitation, University Hospital Ostrava, 70852 Ostrava, Czech Republic
700    1_
$a Klementa, Viktor $u Department of Internal Medicine III-Nephrology, Rheumatology and Endocrinology, University Hospital and Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic $7 xx0275433
700    1_
$a Sigutova, Radka $u Department of Laboratory Diagnostics Institute of Clinical Biochemistry and Clinical Pharmacology, University Hospital Ostrava, 70852 Ostrava, Czech Republic ; Department of Biomedical Sciences Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic
700    1_
$a Kacirova, Ivana $u Department of Laboratory Diagnostics Institute of Clinical Biochemistry and Clinical Pharmacology, University Hospital Ostrava, 70852 Ostrava, Czech Republic ; Institute of Clinical Pharmacology Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic
700    1_
$a Hrabovsky, Vladimir $u Department of Internal Medicine, University Hospital Ostrava, 70852 Ostrava, Czech Republic ; Department of Clinical Studies Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic
700    1_
$a Svagera, Zdenek $u Department of Laboratory Diagnostics Institute of Clinical Biochemistry and Clinical Pharmacology, University Hospital Ostrava, 70852 Ostrava, Czech Republic ; Department of Biomedical Sciences Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic
700    1_
$a Stejskal, David $u Department of Laboratory Diagnostics Institute of Clinical Biochemistry and Clinical Pharmacology, University Hospital Ostrava, 70852 Ostrava, Czech Republic ; Department of Biomedical Sciences Faculty of Medicine, University of Ostrava, 70300 Ostrava, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 21, č. 19 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32993185 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20220808141034 $b ABA008
999    __
$a ok $b bmc $g 1650489 $s 1132499
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 21 $c 19 $e 20200926 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace